EMA Withdrawn: Destara (ibandronic acid) — Roche Registration Ltd.

View source ↗

Summary

Destara (ibandronic acid) has been withdrawn from the European market by Roche Registration Ltd., affecting indications in hypercalcemia and cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hypercalcemia

Drugs mentioned

• Destara (ibandronic acid)

Snippet

Status: Withdrawn. Therapeutic area: Hypercalcemia;Cancer. MAH: Roche Registration Ltd.. Decision date: 31/12/2009